Hugel reported record first-half earnings driven by robust botulinum toxin growth, signaling sustained demand for the injectable category across its portfolio. The South Korean manufacturer's H1 performance reflects continued market appetite for neuromodulators despite competitive pressure from AbbVie's BOTOX, Evolus's Jeuveau, and Daewoong's Nabota.
Business & M&A
Hugel Posts Record H1 Earnings on Toxin Growth
South Korean manufacturer reports strong first-half results driven by botulinum toxin demand.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Record first-half earnings driven by botulinum toxin growth.
For U.S. medspa and cosmetic practice owners, Hugel's momentum underscores the durability of toxin economics even as price competition intensifies. The company's ability to grow earnings—not just revenue—suggests operational leverage in manufacturing and distribution. Owners relying on toxin as a core revenue pillar should monitor Hugel's market share gains and any shifts in their U.S. rebate or loyalty programs, particularly if the company accelerates direct-to-practice outreach to capture share from incumbent players.
Source: original report ↗
Frequently asked questions
Is botulinum toxin still profitable for medspa owners in 2024?
Yes. Hugel's record first-half earnings growth driven by toxin demand demonstrates sustained market appetite for neuromodulators despite competitive pressure from BOTOX, Jeuveau, and Nabota. The company's earnings growth—not just revenue—indicates strong operational leverage, suggesting the category remains economically durable for practices.
What botulinum toxin brands are competing for medspa market share?
The main competitors are AbbVie's BOTOX (market leader), Evolus's Jeuveau, Daewoong's Nabota, and Hugel's products. Hugel's record H1 performance shows it's gaining traction alongside these established players, making it worth evaluating as an alternative supplier.
Should I switch toxin suppliers or negotiate better rebates?
Hugel's momentum and potential acceleration of direct-to-practice outreach suggests leverage for medspa owners to renegotiate terms. Monitor Hugel's rebate and loyalty programs as the company works to capture market share from incumbents—this competitive pressure may create better pricing opportunities across suppliers.
Why does Hugel's earnings growth matter more than revenue growth?
Earnings growth indicates the company is improving operational efficiency and manufacturing leverage, not just selling more units at lower margins. This suggests Hugel can sustain competitive pricing while remaining profitable, making them a more stable long-term supplier for medspa practices.
Is price competition in botulinum toxin getting worse?
Yes, competitive pressure is intensifying from multiple players including BOTOX, Jeuveau, and Nabota. However, Hugel's record earnings despite this competition shows the market can support multiple suppliers—medspa owners should use this fragmentation to negotiate better rebates and loyalty terms.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.